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ABSTRACT A full-length cDNA clone encoding a purified 
augmenter of liver regeneration (ALR) factor prepared from 
the cytosol of weanling rat livers was isolated. The 1.2-kb 
cDNA included a 299-bp 5' untranslated region, a 375-bp 
coding region, and a 550-bp 3' untranslated region. It encoded 
a protein consisting of 125 amino acids. The molecular weight 
of ALR calculated from the cDNA was 15,081, which is 
consistent with the size estimated by SDS IP AGE under re-
ducing conditions. The molecular weight of the purified native 
ALR estimated by SDS/PAGE under nonreducing conditions 
was ""30,000; thus ALR apparently has a homodimeric struc-
ture. The recombinant ALR produced by expression of the 
cDNA in COS cells was tested in vivo in the canine Eck fistula 
model and found to have potency equivalent to the purified 
native ALR. The 125-aa sequence deduced from the rat ALR 
cDNA shows 50% homology to the amino acid sequence of the 
gene for oxidative phosphorylation and vegetative growth in the 
yeast Saccharomyces cerevisiae. 
Heat-stable hepatocyte stimulatory actlVlty has been de-
scribed in the liver of weanling rats and in the regenerating 
liver or serum of adult rats and dogs after partial hepatectomy 
(1-6), We have previously reported the progressive purifi-
cation to x831,000 of the responsible factor (7-11), called 
augmenter of liver regeneration (ALR). This growth factor 
(originally called HSS), which is found in hepatocyte cytosol 
(4-6), does not affect the resting liver, but it augments the 
proliferative response to hepatectomy in rats (4) and dogs (5) 
and dramatically increases the hyperplasia caused by canine 
portacaval shunt (Eck fistula) (6), 
Attempts also have been made by others to purify rat (12, 
13) and human ALR (14, 15), We report here the complete 
amino acid sequence of a 30-kDa band from our purification 
product and the cloning and sequence analysis of its cDNA.11 
Full hepatotrophic activity of the recombinant ALR was then 
demonstrated with the Eck fistula model, and its mRNA 
expression was studied in the tissues of normal rats. 
MATERIALS AND METHODS 
Materials. The cDNA synthesis and cloning systems were 
purchased from Amersham and Pharmacia LKB. Enzymes 
for DNA manipUlation were obtained from Toyobo (Osaka, 
Japan), Plasmid DNAs were purchased from Stratagene and 
Clontech. Radioisotope was purchased from Amersham. 
Purification and Sequencing of Rat ALR. The method of 
purification of ALR from male Fisher weanling rats was as 
reported (9, 10). The procedures involved the following 
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successive steps: ethanol preCIpitation, ultrafiltration 
through an Amicon PM30 membrane, cation-exchange FPLC 
on a Mono Q column, and nondissociating PAGE, The final 
product was applied on SDS/PAGE and contained residual 
bands of 14, 30, and 35 kDa. The 30-kDa band of the final 
product extracted from SDS/PAGE was sliced from the gel 
after staining with Coomassie brilliant blue, digested with 
Iysyl endopeptidase (Achromohacter lyticus protease I) (16), 
and separated with an octyldecyl silica column. Each peak 
was sequenced using the Applied Biosystems 477 A protein 
sequencer. 
Synthesis of Oligonucleotides. Oligonucleotides encoding 
parts of the amino acid sequence of the rat ALR were 
synthesized on the Applied Biosystems 381A DNA synthe-
sizer. 
Extraction of mRNA and Construction of a cDNA Library. 
Total RNA was isolated from the livers of2-week-old rats by 
guanidine isothiocyanate extraction (17), mRNA was purified 
by Oligotex dT30 (Nippon Roche, Tokyo). Three milligrams 
of total RNA was obtained from 1 g of liver, which yielded 
about 30 JLg of mRNA, Double-stranded cDNA synthesized 
with oligo(dT) as a primer was ligated into a Agtll vector with 
EcoRI adapters and packaged in vitro using packaging ex-
tract. Five micrograms of mRNA yielded 1 x 109 phages. 
PCR. Single-stranded cDNA was synthesized from liver 
mRNA primed with 5' -AACTGGAAGAATTCGCGGCCG-
CAddAAEqh~-PD (Pharmacia) and was amplified by PCR 
with the following mixture of 5' primers: 5'-ATIGA(T/ 
C)CGIAG(T /C)CA(A/G)CCIGA(T /C)AC-3', 5' -A TlGA(T / 
C)CGITCICA(A/G )CCIGA(T /C)AC-3', 5' -A TlGA(T / 
C)AG(A/G)AG(T /C)CA(A/G)CCIGA(T /C)AC-3', and 5'-
A TIGA(T /C)AG(A/G)TCICA(A/G)CCIGA(T /C)AC-3', 
where I is inosine, The primers were synthesized on the basis 
of partial amino acid sequences of rat ALR-26 and the 3' 
primer, 5'-GCCGCAGGAA(Tho-3', Then PCR was per-
formed under the following conditions: 95°C for 1 min, 58°C 
for 28 min, and 75°C for 3 min per cycle for 40 cycles using 
Thermus thermophilus DNA polymerase, The PCR products 
were analyzed on an agarose gel, and bands were extracted 
from the gel and subcloned into the EcoRV site ofpBluescript 
by T A cloning (18), 
Screening of a cDNA Library. Replica filters were prepared 
and hybridized with a PCR probe that was generated by 
digestion with Sal I andXha I and labeled with the multi prime 
DNA labeling system (Amersham). The hybridization was 
Abbreviations: ALR, augmenter ofliver regeneration; FCS, fetal calf 
serum. 
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ALR-19 Phe-Tyr-Pro-X-Glu-Glu-X-Ala-Glu-Asp-Ile 
ALR-20 Leu-Gly-Lys-Pro-Asp-Phe-Asp-X-Ser-X-Val 
ALR-26 X-Ile-Asp-Arg-Ser-Gln-Pro-Asp-Thr-Ser-Thr-Arg-
Val-Ser-Phe-X-Gln-X-Leu-X-X-Leu 
FIG.1. Amino acid sequences ofthree peptide fragments derived 
from rat ALR. 
carried out for 12 hr at 6SOC in 4 x SSC containing 5 x 
Denhardt's solution and 80 JLg of denatured salmon testis 
DNA per m!. The filters were then washed at 65°C in 2 x 
SSC/0.1% SDS, air-dried, and autoradiographed on x-ray 
film (19). 
Determination ofthe Nucleotide Sequence. The DNAs of the 
isolated phage clones were extracted (19), digested with 
EcoRl, subcloned into pBluescript, and subjected to nucle-
otide sequence determination by the dideoxynucleotide 
chain-termination method (20). 
Expression by COS-l CeHs. The 5' untranslated G+C-rich 
region (nucleotides 1-278; see Fig. 2) was eliminated, and a 
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HindIII site was introduced by PCR-based in vitro mutagen-
esis. The generated O.S-kb fragment, which includes the 
coding region of ALR cDN A, was inserted into the CDMmcs 
vector (21). The construct was transfected into COS-l cells 
by the DEAE-dextran method (22) modified as follows: after 
the transfection, cells were incubated overnight in DMEM 
plus 10% (vol/vol) fetal calf serum (FCS), and the culture 
medium was changed from DMEM plus 10% FCS to DMEM 
without FCS and incubated for 2 days. Transfected cells were 
separated from culture medium by centrifugation. The cells 
were harvested by scraping and were homogenized in fresh 
DMEM without FCS and followed by centrifugation to get a 
cytosolic fraction. Both the culture medium and the cytosolic 
fraction were assayed for ALR activity. 
Northern Blot Hybridization. To determine the tissue-
specific expression, Clontech's multiple tissue Northern blot 
(MTN blot) was hybridized with the 32P-labeled 1.2-kb EcoRI 
fragment of ALR26-S eDNA for IS hr at 42°C in 50% (vol/vol) 
formamide/S x SSC/10 mM sodium phosphate, pH 6.8/0.S% 
5' -CGCGCGCTGGCGGTGGCATGCGCGCTGCTCTGTCCCGTCTCCTGCACGCCCTCTTGGCC 59 
CCGCTGCTCGTACGCCAGCAATATGGCGGCGCCCAGCGAACCCGCAGGTTTCCCTCGCGGCAGTCGCTTCTCCTTCCTGCCGGGCGGCGCGCACTCGGAGATGACCGACGACCTGGTGAC 179 
TGACGCGCGGGGCCGCGGCGCAAGGCATAGAAAAGACAACGCCCCTGCCGCGGCCCCGGCGCCGAAAGGTTTGGAGCACGGGAAGCACCGTGCCGGGCCTGCGTGGACTTCAAGTCGTGG 299 
ATG CGG ACC CAG CAG AAG CGG GAC ATC AAG TTT AGG GAG GAC TGT CCA CAG GAT CGG GAA GAA TTG GGT CGC AAC ACC TGG GCT TTC cn 389 
M R Q Q K R 0 K R E 0 C P Q 0 R E E G R N W A L 
10 20 30 
CAT ACG CTG GCC GCC TAT TAC CCG GAC ATG CCC ACG CCA GAA CAA CAG CAG GAT ATG GCC CAG TTC ATA CAT ATA TTT TCC AAG TTT TAC 479 
T A A Y Y P 0 M P T P Q Q Q D M A Q S K L-Y. 
40 50 60 
CCC TGT GAG GAG TGT GCA GAA GAC ATA AGG AAG AGG ATA GAC AGG AGC CAG CCA GAC ACA AGC ACT CGA GTG TCC TTC AGC CAG TGG CTG 569 
P C E C A E 0 R K R 0 R S Q P D T S R V S S Q W L 
70 80 90 
TGC CGC cn CAC AAT GAA GTG AAC CGG AAG CTG GGC AAG CCT GAT TTT GAC TGC TCA AGA GTT GAT GAG CGA TGG CGT GAC GGC TGG AAG 659 
C R N E V N R K L G K P 0 D C S R V D E R W R D G W K 
100 110 120 
GAC GGC TCC TGT GAC TAA GGATTACCACAGACCGTGCAGGGCAACGCCGGGTTCTATGGGCAACAGCCTGACTGACGATTAAAGTGCATCTGAGCCAAAGCTTGTTTCTGTGGT 773 
D G S C 0 * 
GGGGGTGGGATCCCCTAGAACACTGCCTATGGGAACCCTACCCACAGACTCAGAAACGGAGGTGCCCACTATAGACAGTTGGGTGGCTTCCTCAGGTCTTAAAGCCCCATGGGACTGAAG 893 
ATGAGAGGCAGGAGTGGTCCAGGGCACCCCATACCCCTTATGATACCCATTATACATTTGGGACATAGTTGCCTCAAAGGAAGGTGGGCTAGACCATTGCCTTCCTACTACATATCCCCA 1013 
GCTGCCTACAGAACTGTGACCCAGGCAACTCTGCCATTTCAGAATTGAAGCAGGGTTCCAGCTCTAGTTGGGTTTTTCTCTTAGGGTAAACCAACCATGGTGCCCACTGTCAGCCTGGCA 1133 
CATGGTCTTCTGCAGCCAGGACAAACATGTCAGCAGAGGATCCTGGGAAGGGCTTCCTTAGCGTTTGAGACCAAAATAAAATGAAGTGACTT -3' 1225 
FIG. 2. Nucleotide sequence of rat ALR cDNA and the deduced amino acid sequence. Amino acid residues are numbered below the 
sequence; nucleotide positions are numbered on the right. Chemically determined peptide sequences are underlined. The poiy(A) additional 
signal is indicated with a double underline. 
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SDS containing 500 fLg of salmon testis DNA per ml (19). The 
filter was then washed three times with 2x SSC/0.1% SDS 
for 30 min, air-dried. and autoradiographed on x-ray film for 
2 days. 
In Vivo Assay of Recombinant ALR. The cytosolic fraction 
and the medium from the transfected COS cell experiment as 
well as the mock homogenate and supernatant (controls) 
were filtered through an Amicon PM30 membrane (30,000 
molecular weight cutoff) and concentrated to a final volume 
of 0.2 ml. Aliquots were dissolved in normal saline containing 
5 mM ammonium acetate and bovine serum albumin at 5 
mg/liter (to prevent adhesion to the plastic tubing). After 
performing completely diverting portacaval shunt, an infu-
sion catheter was inserted into the tied-offleft portal vein for 
pump-driven constant infusion of the test substance over the 
next 4 days (6, 23). At the end of 4 days, the animals were 
injected intravenously with [3Hjthymidine (New England 
Nuclear) at 0.2 mCi/kg (1 Ci = 37 GBq) and killed 2 hr later. 
Specimens were obtained for comparison of the hepatocytes 
in the left (infused) and right (not infused) liver lobes using 
morphometric and autoradiographic techniques (6, 23). Au-
toradiography was carried out with Ilford K2 nuclear emul-
sion with an exposure time of at least 30 days. The number 
of replicating hepatocytes as an index of hepatocyte regen-
eration was determined by counting the number of [3H]thy-
midine-labeled nuclei per 1000 hepatocytes. 
The size of individual hepatocytes (index of hypertrophy or 
atrophy) was determined by tracing out at least 500 mid zonal 
liver cells projected on standard-thickness paper, cutting out 
the individual silhouettes, and weighing each (6, 23). This 
method has been shown to be accurate for determining 
hepatocyte cell size and has been validated by planimetry and 
by studies of unicellular organisms, the size of which has 
been determined directly (24). End points indicating hepa-
totrophic activity were prevention of hepatocyte atrophy and 
augmentation of hepatocyte proliferation in the directly in-
fused lobes only. This method has been shown to screen for 
hepatic growth factors with highly variable chemical struc-
ture and function (6, 23, 25-29). 
RESULTS 
After cleavage of the 30-kDa rat ALR with lysyl endopepti-
dase, the isolated peptides were subjected to amino acid 
~equencing (Fig. 1). We then took the following strategy to 
Isolate rat ALR eDNA: (i) Single-stranded cDNA prepared 
from the livers of2-week-old rats was amplified by PCR with 
a .degenerate oligonucleotide primer as the 5' primer and 
ohgo(dT) as the 3' primer. The =350-bp PCR product was 
detected by agarose gel electrophoresis when PCR was 
performed using 5' mixed primers based on the ALR26 
peptide sequence (lle-Asp-Arg-Ser-Gln-Pro-Asp-Thr) shown 
in Fig. 1 and a 3' oligo(dT) primer. (ii) The primer sequences 
of the candidate PCR products were confirmed. The region 
corresponding to the amino acid sequence of ALR26 as well 
as that of ALR20 was confirmed to be in the deduced amino 
acid sequence from the longest open reading frame. (iii) 
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FIG. 3. Schematic representation of rat ALR eDNA (ALR26-5). 
Restriction sites are shown on the kilobase scale. The noncoding 
region is represented by a line, and the coding region is represented 
by the thick arrow. 
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When this most promising PCR product was used as a probe 
to screen the cDNA library (7.5 x 105), three positive clones 
were confirmed. 
By restriction enzyme mapping and sequence analysis, the 
three clones with insert sizes of about 1.2 kb, 0.95 kb, and 0.8 
kb were found to cover the DNA sequence corresponding to 
the mRNA sequence for the coding region of rat ALR. The 
longest of these cDNA clones (ALR26-5) was characterized 
in detail. The complete cDNA and deduced amino acid 
sequences of rat ALR are shown in Fig. 2. The translation 
initiation site was assigned to the first methionine (ATG) 
codon (nucleotides 300-302). The entire 1.2-kb cDNA in-
cludes three parts (Fig. 3): (i) the 299-bp 5' untranslated 
region, (ii) the 375-bp coding region starting from the putative 
A TG codon and ending at the GAC codon (nucleotides 
672-674), and (iii) the termination codon T AA plus the 550-bp 
3' untranslated region. 
The rat ALR consists of 125 aa and has a calculated 
molecular weight of 15,081. The molecular weight deter-
mined by SDS/PAGE is =15,000 under reducing conditions 
and =30,000 under nonreducing conditions. The native ALR 
has a homodimeric structure. There is no signal peptide 
sequence and no potential N-glycosylation site. 
ALR mRNA Expression in Rat Tissue. The expression of 
ALR mRNA in rat tissues was examined by Northern hy-
bridization with the entire cDNA as a probe using MTN blot 
paper. As shown in Fig. 4, rat ALR mRNA is expressed in 
almost all tissues in relatively low abundance but in high 
abundance in testis. The size of mRNA of ALR is about 1.2 
kb, the same size as the cDNA. 
Production and in Vivo Testing of Recombinant ALR. After 
the ALR expression vector was transfected into COS cells, 
its peptide product was collected from the supernatant and 
separately from the cytosolic fraction of COS cell homoge-
nates. Both were tested in the Eck fistula model (Table 1). 
The vector-COS cytosol and supernatant contained no ac-
tivity (negative controls). Recombinant hepatocyte growth 
factor, which also is produced in COS cells and is known to 
be hepatotrophic in the Eck fistula model (26), was a positive 
control. 
A dose-dependent stimulation of DNA synthesis was de-
~ected only in the cytosolic fraction (dog 5, Table 1) but not 
In the culture supernatant (dog 4, Table 1). This activity was 
abolished by the same anti-ALR monoclonal antibody (dog 6, 
Table 1) that eliminated activity ofthe native purified peptide 
(11). 
The recombinant ALR also prevented the hepatocyte 
atrophy of Eck fistula on the treated side of the liver but not 
the other (Table 1). The ultrastructure of the protected 
hepatocytes was normal, whereas hepatocytes in the control 
(untreated) liver showed a great decrease in the amount of 
12345678 
(kb) 
FIG. 4. Northern blot analysis of rat ALR: expression of the rat 
ALR mRNA in various adult rat tissues. Lane I, heart; lane 2, brain; 
lane 3, spleen; lane 4, lung; lane 5, liver; lane 6, skeletal muscle; lane 
7, kidney: lane 8, testis. The arrow indicates the location ofrat ALR 
mRNA. 
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Table 1. Tests in the Eck fistula assay 
Hepatocyte Labeled 
size. hepatocytes 
Dog Side(s) size units (per thousand) 
no. Infusate infused Left Right Left Right 
HGF supernatant Left 0.156 0.088 11.0 5.3 
2 Vector-COS cytosol (NC) Left 0.103 0.099 6.3 5.4 
3 Vector-COS supernatant (NC) Left 0.103 0.101 3.8 4.0 
4 ALR-26 supernatant (40 ng/kg) Left 0.079 0.103 6.4 6.6 
5 ALR-26 cytosol (40 ng/kg) Left 0.163 0.090 15.2 4.8 
6 ALR-26 cytosol (20 ng/ml) to 
both + mAb to right Both 0.150 0.104 10.1 5.1 
Infusions were for 4 days immediately after the completely diverting portacaval shunt. The human 
hepatocyte growth factor (HGF) cDNA expression vector (del-HFG) was used for transfection (21). 
Hepatocyte growth factor previously was shown to be hepatotrophic (26), and this was a positive 
control of the assay. NC, negative control; mAb, monoclonal antibody. 
rough endoplasmic reticulum and in the number of ribosomes 
on the membranes. The Golgi apparatus in these hepatocytes 
was poorly developed, and some of the mitochondria were 
enlarged and their cristae were disrupted. 
The foregoing results were confirmed 2 months later with 
the next batch of COS cell ALR (data not shown). 
DISCUSSION 
The unique features of the Eck fistula assay, which was used 
in previous studies of native ALR and other growth factors 
(6, 10. 23, 25-29), assured accurate assessment of hepa-
totrophic activity in the current series of single dog experi-
ments. With the Eck fistula model, the untreated portion of 
the liver provides an internal control for the treated part. The 
histopathologic end points are determined blindly and assem-
bled without knowledge of the experiment. The effective 
dose range, 20-40 ng/ml, established in dogs 5 and 6 for the 
recombinant peptide was essentially the same as the 20-50 
ng/kg range previously reported for the native ALR (10, 26). 
The development of the crucial Eck fistula assay as well as 
our interest in ALR stemmed from research on auxiliary liver 
transplantation. It was observed that coexisting livers (one an 
allograft) (30), or alternatively the coexisting two fragments 
of an animal's own divided liver (24, 31), competed for 
unknown growth-modulating substances in the portal venous 
blood, which, when consumed by one liver or fragment, 
resulted in the acute atrophy of the other. The Eck fistula 
assay, which is a sophisticated double liver model, made it 
possible to prove in 1975 that insulin was the principal 
splanchnic hepatotrophic portal blood factor (23, 25). With 
the operation ofEck's fistula (portacaval shunt), the liver was 
deprived of portal venous blood, leaving it with an arterial 
supply only. Within 4 days, the hepatocytes shrink to half 
size, and the rate of resting cell renewal triples-an abnormal 
state that remains stable thereafter. Nonhypoglycemic doses 
10 20 
ALR26 1 l-IRTQQKRDIK cobaC~nl;1Ko~ 
SCERV1 1 l-IPGSRT---- vohsa1DKml;1Ks~ 
60 70 
ALR26 51 ~fefcphcu PCEECAEl;1.IR 
SCERV1 51 ~ikfcpefu PCNWCAKl;1.FE 
110 120 
ALR26 101 ~dhmacaCpo VDERWRDGWK 
SCERV1 101 ~ohmhcaCkc WEKRWKDGWD 
of insulin infused into a principal branch ofthe tied-off central 
portal vein prevented the atrophy in the lobes supplied by this 
branch but not on the other side. In addition the insulin 
produced sustained unilateral proliferation (23, 25). Collec-
tively, these two growth effects have been called hepa-
totrophic. 
Our attention in 1978 turned upstream to the liver as a 
possible source of self-generated paracrine or humoral 
growth control factor(s) with the same hepatotrophic effects. 
When cytosol from regenerating dog livers was tested in the 
Eck fistula model, it protected the portaprival liver in the 
same way as insulin (6). Efforts to identify and purify the 
active constituent in the cytosol of rat livers were hampered 
by the inability to settle on an appropriate assay. Fractions 
prepared by other investigators were reported to be mitoge-
nic in tissue cultures ofhepatocytes or hepatoma cells (12,13, 
15), whereas ours were inert in vitro throughout purification 
to the final fraction used for amino acid sequence analysis and 
cDNA cloning (9, 10, 26). 
In vivo testing was difficult with the assay of LaBrecque 
and Pesch because the variability of the regeneration nor-
mally following partial hepatectomy (4, 9) made it difficult to 
quantitate the augmentation of this response with cytosol or 
its purified derivatives. Consequently, after establishing the 
species non specificity of our weanling rat fractions (9), we 
returned to the highly reproducible Eck fistula assay with 
which a comparison cell size and mitotic activity in treated 
versus nontreated liver fragments allowed each animal to 
provide its own control (10, 11). 
The recombinant ALR eventually produced by the gene 
derived from the purified rat cytosol retained the same 
hepatotrophic potency as the native peptide in the Eck fistula 
assay while having no effect on cultured hepatocytes. No 
ALR could be found in the culture medium of COS cell 
transformants, indicating that the recovered ALR activity 
was intracellular in origin. Because ALR lacks a stretch of 
30 40 50 
bidokq~Ac~ RTLAAYYPDM mqmbnnna~ 50 
nidoppkqi~ RSVAASYPAQ PTDQQKGEl-IK 50 
80 90 100 
ho!aopn~aq pqospcpn~i ~oiekbskoh 100 
hv!obkA~ns ESREELGRNM ~bAekhskhh 100 
130 140 150 
DGSCD ..... . . . . . . . .. . . .................. 150 
E---- ..... ................ . . .. . . . . . . . 150 
FIG. 5. Alignment of amino acid sequences of rat ALR (ALR26) and yeast ERV1 (SCER VI). Gaps were introduced to optimize the homology. 
Identical residues are in boldface type and are underlined. 
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hydrophobic amino acids, either N-terminal or internaL 
which could act as a signal sequence, we do not know if and 
how ALR is secreted from the cells of the liver. However. it 
is possible that ALR is secreted through a novel pathway, as 
has been suggested for interleukin IB and thioredoxin, which 
may involve translocation of intracellular membranes, rather 
than the classical endoplasmic reticulum-Golgi route (32), 
depending on the cell types. Since ALR does not directly 
stimulate hepatocytes in culture, its powerful hepatic growth 
effects in vim may be through the regulation of nonparen-
chymal cells, and, if so, this will be a link with the immune 
system. 
As with insulin, the effects of ALR go beyond the aug-
mentation of hepatocyte proliferation and maintenance of cell 
size. ALR and other major hepatotrophic substances identi-
fied with the Eck fistula model prevent disruption of the 
rough endoplasmic reticulum, mitochondria, and other or-
ganelles. These other agents are insulin (23. 25), insulin-like 
growth factor (26), transforming growth factor Q' (26), hepa-
tocyte growth factor (26), the immunosuppressive agents 
cyclosporine (27) and FK 506 (28). and the recombinant 
immunophilin FKBP12 (29). The possibility must be consid-
ered that their remarkably similar end points are reached by 
a common intermediary molecular mechanism involving 
ALR. 
While ALR has no structural relationship to any of these 
other hepatotrophic factors. it has an =50% amino acid 
homology with nuclear gene ERVI (Fig. 5), which is essential 
for oxidative phosphorylation, vegetative growth, and life of 
the yeast Saccharomyces cerevisiae (33). This is one of the 
few dual-function nuclear genes that are not only part of the 
mitochondrial respiratory chain but also playa critical role in 
cell growth regulation (34). Disruption of the gene causes a 
severe growth defect and irreversible cessation of cell divi-
sion after 3-4 days (33). A mammalian homologue of the 
ERV1 gene has not been reported, and the ALR gene may be 
it. 
With the availability of the ALR gene and its recombinant 
product, a range of questions can be addressed about its 
production. secretion, mechanisms, and importance. Con-
trary to previous belief, the variable RNA expression in 
nonhepatic tissues suggests that ALR is not liver specific but 
would be expressed by other cells under the appropriate 
circumstances of proliferation. 
The potential clinical implications of ALR for the treatment 
of liver disease. including fulminant hepatic failure, have 
been evident for some time (7). 
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